You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CATAPRES-TTS-2 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Catapres-tts-2, and what generic alternatives are available?

Catapres-tts-2 is a drug marketed by Lavipharm and is included in one NDA.

The generic ingredient in CATAPRES-TTS-2 is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Catapres-tts-2

A generic version of CATAPRES-TTS-2 was approved as clonidine by AVEVA on August 18th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CATAPRES-TTS-2?
  • What are the global sales for CATAPRES-TTS-2?
  • What is Average Wholesale Price for CATAPRES-TTS-2?
Drug patent expirations by year for CATAPRES-TTS-2
Recent Clinical Trials for CATAPRES-TTS-2

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rigshospitalet, DenmarkPhase 2/Phase 3
Deventer ZiekenhuisPhase 3
University of EdinburghPhase 3

See all CATAPRES-TTS-2 clinical trials

Pharmacology for CATAPRES-TTS-2

US Patents and Regulatory Information for CATAPRES-TTS-2

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CATAPRES-TTS-2

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 ⤷  Sign Up ⤷  Sign Up
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 ⤷  Sign Up ⤷  Sign Up
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 ⤷  Sign Up ⤷  Sign Up
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 ⤷  Sign Up ⤷  Sign Up
Lavipharm CATAPRES-TTS-2 clonidine SYSTEM;TRANSDERMAL 018891-002 Oct 10, 1984 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CATAPRES-TTS-2

See the table below for patents covering CATAPRES-TTS-2 around the world.

Country Patent Number Title Estimated Expiration
Romania 75336 ⤷  Sign Up
Denmark 117000 ⤷  Sign Up
Sweden 353721 ⤷  Sign Up
Australia 2846277 ⤷  Sign Up
United Kingdom 1016514 ⤷  Sign Up
Bulgaria 29866 METOD ZA POLUCHAVANE NA TERAPEVTICHNA SISTEMA ZA TRANSDERMALNA UPOTREBA (METHOD FOR OBTAINING OF TERAPEUTICAL SYSTEM FOR TRANSDERMAL APPLICATION) ⤷  Sign Up
Denmark 387777 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.